Increased mTOR expression and phosphorylation were observed in close to 90% of NSCLC patients with adenocarcinoma, while 60% of patients had large cell carcinoma and 40% of patients had squamous cell carcinoma (42–44). This evidence concerns the gene MTOR and large cell carcinoma.